WO2012128520A3 - Liquid-type composition for treating gastroesophageal reflux disease - Google Patents

Liquid-type composition for treating gastroesophageal reflux disease Download PDF

Info

Publication number
WO2012128520A3
WO2012128520A3 PCT/KR2012/001949 KR2012001949W WO2012128520A3 WO 2012128520 A3 WO2012128520 A3 WO 2012128520A3 KR 2012001949 W KR2012001949 W KR 2012001949W WO 2012128520 A3 WO2012128520 A3 WO 2012128520A3
Authority
WO
WIPO (PCT)
Prior art keywords
liquid
reflux disease
gastroesophageal reflux
type composition
treating gastroesophageal
Prior art date
Application number
PCT/KR2012/001949
Other languages
French (fr)
Korean (ko)
Other versions
WO2012128520A2 (en
Inventor
김정훈
진성규
강경훈
김보견
이혜주
Original Assignee
동아제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동아제약 주식회사 filed Critical 동아제약 주식회사
Publication of WO2012128520A2 publication Critical patent/WO2012128520A2/en
Publication of WO2012128520A3 publication Critical patent/WO2012128520A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a novel composition for treating a gastroesophageal disease. A liquid composition for oral administration, according to the present invention, is advantageous in being convenient for the patient to consume due to low viscosity, in having a simple manufacturing process, and in being easy to sterilize, and effectively treats the gastroesophageal disease by forming a floating gel that has superior structural strength.
PCT/KR2012/001949 2011-03-23 2012-03-19 Liquid-type composition for treating gastroesophageal reflux disease WO2012128520A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110025860A KR20120108218A (en) 2011-03-23 2011-03-23 The liquid version composition for the treatment of gastroesophageal reflux disease
KR10-2011-0025860 2011-03-23

Publications (2)

Publication Number Publication Date
WO2012128520A2 WO2012128520A2 (en) 2012-09-27
WO2012128520A3 true WO2012128520A3 (en) 2012-11-15

Family

ID=46879876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001949 WO2012128520A2 (en) 2011-03-23 2012-03-19 Liquid-type composition for treating gastroesophageal reflux disease

Country Status (2)

Country Link
KR (1) KR20120108218A (en)
WO (1) WO2012128520A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016048059A1 (en) * 2014-09-24 2016-03-31 주식회사 태준제약 Composition for treating gastrointestinal diseases, containing alginic acid or alginate and glycyrrhiza uralensis fischer extract
KR102309593B1 (en) * 2019-06-26 2021-10-07 재단법인 강릉과학산업진흥원 Functional beverage composition for gastro-health comprising sodium alginate as an active ingredient and the method for preparing the same
WO2024030936A1 (en) 2022-08-02 2024-02-08 Nutrition & Biosciences Usa 1, Llc Modified-release alginate-based composition
WO2024030933A1 (en) 2022-08-02 2024-02-08 Nutrition & Biosciences Usa 1, Llc Novel alginate and cellulose derivative based composition of the liquid anti-reflux formulation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744986A (en) * 1986-03-07 1988-05-17 Rorer Pharmaceutical Corporation Process for the preparation of a viscosity-stable antacid composition
WO1996027368A1 (en) * 1995-03-03 1996-09-12 Reckitt & Colman Products Limited Liquid aqueous pharmaceutical compositions comprising sodium alginate and potassium bicarbonate
US20050089577A1 (en) * 2002-03-04 2005-04-28 Hideakira Yokoyama Liquid matrix undergoing phase transfer in vivo and liquid oral preparations
US20080317855A1 (en) * 2005-07-28 2008-12-25 Reckitt Benckiser Healtcare (Uk) Limited, Particulate Compositions Comprising Alginate and/or Alginic Acid

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744986A (en) * 1986-03-07 1988-05-17 Rorer Pharmaceutical Corporation Process for the preparation of a viscosity-stable antacid composition
WO1996027368A1 (en) * 1995-03-03 1996-09-12 Reckitt & Colman Products Limited Liquid aqueous pharmaceutical compositions comprising sodium alginate and potassium bicarbonate
US20050089577A1 (en) * 2002-03-04 2005-04-28 Hideakira Yokoyama Liquid matrix undergoing phase transfer in vivo and liquid oral preparations
US20080317855A1 (en) * 2005-07-28 2008-12-25 Reckitt Benckiser Healtcare (Uk) Limited, Particulate Compositions Comprising Alginate and/or Alginic Acid

Also Published As

Publication number Publication date
KR20120108218A (en) 2012-10-05
WO2012128520A2 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
JO3199B1 (en) Substituted 5-fluoro-1H-pyrazolopyridines and their use
EA201490546A1 (en) SUBSTITUTED ANNELED PYRIMIDINES AND THEIR APPLICATION
MX2015009037A (en) Honey nasal rinse.
EA201291034A1 (en) APTAMERS TO β-NGF AND THEIR APPLICATION IN THE TREATMENT OF B-NGF-MEDIATED DISEASES AND DISORDERS
UA105487C2 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
EA201300669A1 (en) SUBSTITUTED 1-BENZYL CYCLOALKYL CARBONIC ACIDS AND THEIR APPLICATION
EA201200551A1 (en) PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSED FORM, METHODS OF THEIR PRODUCTION AND APPLICATION FOR TREATMENT
WO2014004902A3 (en) Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
BR112012009043A2 (en) double-domain variable immunoglobulins and their use
EA201892050A1 (en) METHOD OF OBTAINING SUBSTITUTED 5-FLUOR-1H-PYRAZOLOPIRIDINES
DK3045456T3 (en) BICYCLICALLY SUBSTITUTED URACILES AND APPLICATION
MX2013011124A (en) Compounds for treatment of metabolic syndrome.
CR20110552A (en) TREATMENT OF INSULIN RESISTANT DISORDERS
WO2012128520A3 (en) Liquid-type composition for treating gastroesophageal reflux disease
PH12014502071A1 (en) Beta-hydroxy-beta-methylbutyric acid for imrpoving glucose tolerance
MX2013003160A (en) Antidiabetic solid pharmaceutical compositions.
EA200970816A1 (en) NEW MEDICINE FORM
MX2013002261A (en) Substituted n-phenethyltriazoloneacetamides and use thereof.
WO2009152052A8 (en) Methods of treating alpha adrenergic mediated conditions
WO2012150607A3 (en) Oral liquid composition comprising divalproex sodium and process for preparing thereof
WO2011093647A3 (en) Genes implicated in osteoarthritis and use thereof
GEP20156373B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
HK1172568A1 (en) Soluble pharmaceutical forms of n,n-diaminodiphenyl sulphone for optimum use in the treatment of various diseases nn-
FR2974989B1 (en) BED, IN PARTICULAR MEDICALIZED BED FOR THE TREATMENT OF HOME PATIENTS
WO2011161295A3 (en) Use of anticalcineurin compounds for the treatment of pathologies involving ocular neovascularisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12760933

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12760933

Country of ref document: EP

Kind code of ref document: A2